Abaloparatide, which had been developed as a new analog (101) for therapeutic use in osteoporosis, is identical to PTHrP in its first 21 residues, but has 8 residues different from PTHrP between 22 and 34, and is equipotent with PTH peptides in the standard bioassay of total cell cAMP generation in target cells (79, 100, 102). The gene discussed is PTH; the disease is osteoporosis.